As of September 9, 2026, federal multidistrict litigation MDL 2738 remains pending. The September 1, 2026 Judicial Panel on Multidistrict Litigation report lists 69,250 actions pending in that federal MDL alone—not a nationwide total. On July 27, 2026, Johnson & Johnson (J&J) announced a proposed $5.5 billion resolution for remaining ovarian-talc claims. The proposal is conditioned in part on participation by firms representing at least 95% of remaining claims and is not yet a final individualized payment program. Mesothelioma claims involve a different alleged pathway—asbestos-contaminated talc—and are not part of this ovarian-claim proposal.

Current Status as of September 2026

J&J's second-quarter 2026 SEC filing reported approximately 76,000 direct U.S. plaintiff claims as of June 28, 2026. The 10-Q does not expressly label that figure ovarian-only, while J&J's July 27 announcement describes an apparently similar figure as ovarian-talc claims; the precise scope should therefore be treated as unresolved absent further company clarification. The company-reported figure also differs in source, date, and scope from the JPML's later federal MDL-only count, so the two numbers should not be added together or treated as interchangeable. According to J&J's SEC-filed announcement, on July 22, 2026 the MDL court ordered plaintiffs to show why the remaining pending talc claims should not be dismissed for inability to prove specific causation, following the withdrawal of two specific-causation experts in two bellwether cases. The show-cause order was procedural; it did not itself dismiss the MDL or decide every claimant's case.

The proposal described here is dated July 27, 2026 and remains conditional; its participation and payment terms should be checked against later court-docket or company filings before anyone relies on them. Separately, on March 31, 2025, the bankruptcy court denied confirmation and dismissed Red River Talc's Chapter 11 case. The underlying bankruptcy docket record may require PACER access, and an official January 2026 federal MDL opinion publicly recounts the ruling. The litigation therefore continues outside that dismissed bankruptcy proceeding.

[talcum_long_1]

Which Claim Path Fits the Facts?

Prospective plaintiffs generally fall into one of two distinct legal categories based on their diagnosis and the nature of their talc exposure.

Fast Evidence Checklist

To evaluate a potential claim, legal counsel typically requires a specific set of documentation. Gathering these items is the first step in determining eligibility:

• Product identification: Specific brand names, packaging, manufacturers, and any surviving containers, photographs, receipts, or purchase records.
• Usage history: Estimated start and end dates, frequency, and the route of application, including whether use was perineal or involved inhalation.
• Medical diagnosis: Pathology and treatment records identifying the cancer type and date of diagnosis.
• Alternative exposures and risk factors: Other potential asbestos exposures for mesothelioma and relevant medical or family history for ovarian cancer.
• Geographic record: States where the product was purchased and used and where the claimant lived, because governing law and deadlines may differ.
• Witnesses and corroboration: People who observed product use and records that can connect a specific product to the claimant.

[talcum_long_2]

What the July 2026 Proposal Means

The $5.5 billion commitment announced by J&J on July 27, 2026, is a proposed settlement framework, not a guaranteed payout.

1. Scope: J&J described it as a proposed resolution of remaining ovarian-talc claims, not mesothelioma claims.
2. Participation condition: J&J's SEC-filed announcement says the proposal is conditioned in part on firms representing at least 95% of remaining claims agreeing to participate.
3. Per-claim structure, but no promised individual amount: J&J says the proposal calls for per-claim payments, with a first payment of no more than $3 billion in 2027 and no additional payments due before 2028. It does not publish a guaranteed dollar amount for an individual claimant or support a reliable “average settlement” calculation.
4. No automatic qualification: A pending or potential claim does not by itself establish eligibility for payment. Final participation rules and individual outcomes cannot be assumed from the headline amount.

[talcum_qualify_short_1]

General vs. Specific Causation

A central hurdle in talc litigation is the distinction between two types of causation. General causation asks if talcum powder is capable of causing cancer in the general population. Specific causation asks if talcum powder actually caused the cancer in one specific plaintiff. The July 2026 settlement proposal is a business resolution; it does not constitute a legal or scientific admission that talc caused every claimant's injury. Courts continue to evaluate these factors on a case-by-case basis during the discovery process.

Science Without Overclaiming

On July 5, 2024, the International Agency for Research on Cancer (IARC) classified talc as “probably carcinogenic to humans” (Group 2A). IARC reported limited evidence in humans for ovarian cancer, sufficient evidence in experimental animals, and strong mechanistic evidence.

The classification identifies a cancer hazard; it does not prove that a particular product caused a particular person's disease. The FDA's talc information explains that talc and asbestos can occur near one another geologically and that asbestos is a known human carcinogen. FDA also states that it withdrew its proposed standardized asbestos-testing-method rule for talc-containing cosmetics on November 28, 2025, so that proposal did not become a final rule. J&J disputes the allegations and maintains that its talc products did not cause cancer. That is the company's position, not an adjudicated conclusion applicable to every claim.

Product Status and Regulatory History

Consumer access to talc-based powders has changed significantly in recent years:

• 2020: J&J discontinued talc-based Baby Powder in the United States and Canada. The company attributed the decision to reduced demand and what it called misinformation about product safety.
• August 2022 announcement; 2023 target: J&J announced that talc-based Baby Powder would be discontinued globally in 2023 as the portfolio transitioned to a cornstarch-based formula.
• 2024: A consumer-protection consent judgment announced by the New York Attorney General required a $700 million payment to a coalition of 42 attorneys general and restricted J&J from manufacturing, marketing, promoting, selling, or distributing talc-based Baby Powder and body powder in the United States. This was a consumer-protection matter, not an individualized personal-injury award.

[talcum_long_3]

Factors Affecting Claim Value

It is important to reject "average settlement" figures or headline-grabbing jury verdicts as a baseline for individual cases. The value of a claim is highly variable and influenced by:

• Diagnosis and pathology: The disease and medical evidence must match the claim theory.
• Exposure and causation proof: Product identification, route, duration, frequency, corroboration, expert evidence, and alternative causes can all matter.
• Damages: Medical expenses, future care, lost income, pain and suffering, and other recoverable losses depend on the facts and governing law.
• Venue and procedural posture: The court, applicable state law, MDL status, available defendants, and defenses can affect the path and outcome.
• Appellate and collection risk: A verdict can be reduced, reversed, retried, or remain disputed; a headline verdict is not a rate card for another claim.

[talcum_statute_short_1]

Deadlines and Next Steps

There is no universal deadline for filing a talcum powder lawsuit. State limitation periods and discovery rules differ, and the relevant dates may include diagnosis, discovery of a potential claim, exposure, residence, filing location, or other jurisdiction-specific facts. Preserve product and medical evidence and obtain advice about the law that applies to the individual claim as soon as possible.

[talcum_compensation_short_1]

How to Weigh the Sources

Use a source-quality ladder when evaluating a talc update:

1. Court dockets and orders establish what a court filed, ordered, dismissed, or left pending.
2. Agency and intergovernmental scientific sources such as FDA and IARC explain regulatory or hazard assessments, but do not decide specific causation in an individual lawsuit.
3. SEC filings and party statements can establish what J&J announced or reported; disputed positions must remain attributed to the company.
4. News reports can supply context but should be checked against the underlying filing, order, or agency publication.
5. Law-firm marketing pages may help identify questions to investigate, but they should not control dates, claim counts, eligibility, deadlines, or likely compensation.

Litigation Timeline

• July 27, 2026: J&J announces a proposed $5.5 billion resolution for remaining ovarian-talc claims, conditioned in part on participation by firms representing at least 95% of those claims.
• March 31, 2025: The bankruptcy court denies confirmation and dismisses Red River Talc's Chapter 11 case.
• July 5, 2024: IARC classifies talc as probably carcinogenic to humans (Group 2A), a hazard classification that does not prove specific causation in an individual case.
• June 1, 2021: The U.S. Supreme Court docket records denial of certiorari in Johnson & Johnson v. Ingham. The denial left the lower-court judgment in place but was not a Supreme Court endorsement of the merits.

Legal.com Liability Disclaimer

All content published by Legal.com is provided for general informational purposes only. It is not legal advice, does not constitute a legal opinion, and should not be relied upon as a substitute for consultation with a qualified attorney. No attorney-client relationship is created by reading this article, using Legal.com templates, or contacting Legal.com. Legal.com disclaims all liability for actions taken or not taken based on this publication.